WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006088481) GENETICALLY ENGINEERED EQUINE INFLUENZA VIRUS AND USES THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/088481    International Application No.:    PCT/US2005/019383
Publication Date: 24.08.2006 International Filing Date: 01.06.2005
IPC:
A61K 39/00 (2006.01), A61K 39/295 (2006.01), A61K 39/12 (2006.01), A61K 39/145 (2006.01), C12N 15/64 (2006.01), C12N 5/00 (2006.01), A61K 39/116 (2006.01)
Applicants: MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY [US/US]; One Gustave L. Levy Place, New York, NY 10029-6574 (US) (For All Designated States Except US).
UNIVERSITY OF KENTUCKY [US/US]; A144 AsteCC Building, Lexington, KY 40506-0286 (US) (For All Designated States Except US).
PALESE, Peter [US/US]; (US) (For US Only).
GARCIA-SASTRE, Adolfo [US/US]; (US) (For US Only).
CHAMBERS, Thomas [US/US]; (US) (For US Only)
Inventors: PALESE, Peter; (US).
GARCIA-SASTRE, Adolfo; (US).
CHAMBERS, Thomas; (US)
Agent: CORUZZI, Laura, A.; Jones Day, 222 East 41st Street, New York, NY 10017-6702 (US)
Priority Data:
60/653,588 15.02.2005 US
Title (EN) GENETICALLY ENGINEERED EQUINE INFLUENZA VIRUS AND USES THEREOF
(FR) VIRUS DE LA GRIPPE EQUINE GENETIQUEMENT MODIFIE ET UTILISATIONS ASSOCIEES
Abstract: front page image
(EN)The present invention relates, in general, to attenuated equine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated equine influenza viruses having modifications to an equine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.
(FR)L'invention concerne, d'une manière générale, des virus de la grippe équine atténués présentant une capacité limitée pour freiner la réponse cellulaire d'un interféron IFN, ainsi que l'utilisation de ces virus atténués dans des formulations pharmaceutiques et de vaccins. Plus précisément, l'invention concerne des virus de la grippe équine atténués présentant des modifications d'un gène NS1 équin qui diminue ou élimine la capacité du produit génique NS1 à freiner la réponse cellulaire de l'IFN. Ces virus se répliquent in vivo tout en présentant une réplication et une virulence réduites, et une atténuation accrue et, par conséquent, ils conviennent parfaitement pour des vaccins antiviraux vivants, et des formulations pharmaceutiques.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)